DEVOTENCT07734064
A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Start date pushed from Aug 10, 2026 to Aug 14, 2026
- Study sites: 3 to 4
- Notable Eligibility criteria expanded, about 35 words
- Study sites: 1 to 3
- Secondary endpoints: details revised at 1 of 14 entries
- Notable Recruitment opened
- Study sites: 0 to 1
- Start date changed from estimate of Jul 31, 2026 to Aug 10, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (14)
Show 9 moreShow less
Arms and interventions
Adult participants will receive a single low dose of ASP2020 on Day 1, administered by subretinal injection as part of a surgical procedure, followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Adult participants will receive a single high dose of ASP2020 on Day 1, administered by subretinal injection as part of a surgical procedure, followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Adolescent participants will receive single low dose of ASP2020 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Adolescent participants will receive single high dose of ASP2020 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Adult participants will receive single optimal dose of ASP2020 established in part 1 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Pediatric participants will receive single optimal dose of ASP2020 established in part 1 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Drugs: ASP2020
Sites
4 sites in 1 country